A Novel Pharmacological Therapy for Obstructive Sleep Apnea

Status Recruiting

Clinical Trial Summary

A pharmacological, non-mechanical therapy for OSA that is efficacious and tolerable remains elusive. Here the investigators study the effect on sleep apnea severity of a combination of pharmacological agents (atomoxetine and oxybutynin, "AtoOxy") over a 1 month period of time. The current study will answer the following questions: Does ongoing, repeated-dose administration of atomoxetine-plus-oxybutynin (referred to as "AtoOxy") improve OSA severity, and do patients exhibit signs of symptomatic relief? Most importantly, which phenotypic subgroup of patients preferentially benefit from this intervention?

Clinical Trial Description

Aim 1 - Effect of AtoOxy on sleep apnea severity. In a randomized controlled double-blind crossover study, 48 patients with moderate-to-severe OSA will take atomoxetine-plus-oxybutynin ("AtoOxy") versus placebo nightly for 1 month, with a 2-week washout in between. The investigators will test the hypothesis that AtoOxy reduces the Apnea-hypopnea index (primary outcome measure), and improves the following secondary outcomes: - Nocturnal oxygenation, per "hypoxic burden of sleep apnea" - Frequency of arousals from sleep (Arousal index) - Self-reported sleepiness (Epworth Sleepiness Scale) - Disease-specific quality of life (Functional Outcomes of Sleep Questionnaire, Short Form). - Disease-specific quality of life (Sleep Apnea Quality of Life Index, Short Form) Additional pre-specified exploratory outcome measures will be assessed, including Visual Analog Scales (Sleep Quality, Treatment Satisfaction) and additional polysomnographic measures of sleep (Stage 1 sleep, %total sleep time). Adherence and adverse events will also be carefully monitored to assess repeated-dose tolerance of the intervention. Aim 2 - Determine which patient phenotypes respond best to AtoOxy. Patients will also take part in an additional night before initiating study medication to measure the key mechanisms causing OSA. The investigators will prospectively test the hypothesis that greater pharyngeal collapsibility determines a reduced response to therapy. They will also separately test the hypotheses that a reduced muscle responsiveness, reduced baseline muscle activation, a higher arousal threshold, and a lower loop gain will facilitate a greater response to therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03919955
Study type	Interventional
Source	Brigham and Women's Hospital
Contact	Scott A Sands, PhD
Phone	6172780911
Email	sasands@bwh.harvard.edu
Status	Recruiting
Phase	Phase 2
Start date	September 3, 2019
Completion date	October 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05582070` - Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction	N/A
Completed	`NCT03927547` - Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders	N/A
Recruiting	`NCT04007380` - Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI	N/A
Completed	`NCT02188498` - Electrocardiography Data Analysis in Sleep Disorders
Completed	`NCT01503164` - Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism	N/A
Recruiting	`NCT00747890` - Surgical Treatment of Mild Obstructive Sleep Apnea	N/A
Active, not recruiting	`NCT00738179` - Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease	Phase 3
Completed	`NCT00841906` - Alice PDx User/Validation Extended Trial	N/A
Completed	`NCT00202501` - Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome	N/A
Completed	`NCT00047463` - Effects of Treating Obstructive Sleep Apnea in Epilepsy	Phase 2
Not yet recruiting	`NCT06029881` - Portable System for Non-intrusive Monitoring of Sleep
Recruiting	`NCT06093347` - Central Apnoea Monitor Study
Recruiting	`NCT05445869` - Severe OSA Study (SOS)	N/A
Withdrawn	`NCT04096261` - The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
Recruiting	`NCT04575740` - Phenotyping Mechanistic Pathways for Adverse Health Outcomes in Sleep Apnea	N/A
Completed	`NCT04676191` - Validation of a Contactless Vital Signs Measurement Sensor	N/A
Recruiting	`NCT06015620` - Comorbidities Resolution After MGB Surgery and Change in Body Composition
Completed	`NCT06051097` - Metabolic Syndrome and Obstructive Sleep Apnea
Recruiting	`NCT05687097` - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
Recruiting	`NCT05197855` - Sleep Quality Evolution: Dreem Under CPAP	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.